Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30346072 | 1.00 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL4242310 | 0.84 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL5617751 | 0.83 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL4242900 | 0.83 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL4245048 | 0.81 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL4246947 | 0.80 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL4241679 | 0.79 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL4240274 | 0.79 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL4242099 | 0.78 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL1486431 | 0.78 | TLR7 (0.52) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240417738-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION | 2024-12-19 | — | — | US | disclosed |
| US-20240033348-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Pulmotect, Inc. | 2024-02-01 | — | — | US | disclosed |
| US-11826422-B2 | Methods and compositions for adaptive immune modulation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023070132-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20200345842-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-05 | — | — | US | disclosed |
| US-10722573-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3538218-A2 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | The Board of Regents of The University of Texas System (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190269773-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-09-05 | — | — | US | disclosed |
| US-8883174-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| US-8871782-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120082700-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2012-04-05 | — | — | US | disclosed |
| US-7560436-B2 | Methods of treating gastrointestinal inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1673087-A4 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-04 | — | — | US | disclosed |
| EP-1673087-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005032484-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | IL2, IFNG, IRF3 | TLR7 36/4885TLR8 129/4885 |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | IFNG, IFNAR1, TNF | TLR7 38/4885TLR8 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.